HC Wainwright set a $60.00 price objective on Uniqure (NASDAQ:QURE) in a report published on Tuesday. The firm currently has a buy rating on the biotechnology company’s stock.
Several other equities research analysts have also issued reports on QURE. Cantor Fitzgerald set a $58.00 price target on Uniqure and gave the company a buy rating in a report on Saturday, August 11th. Chardan Capital reiterated a buy rating and set a $50.00 price target on shares of Uniqure in a report on Thursday, October 18th. Cowen reiterated a buy rating on shares of Uniqure in a report on Monday, August 13th. B. Riley lifted their price target on Uniqure from $50.00 to $72.00 and gave the company a buy rating in a report on Friday, November 16th. Finally, BidaskClub upgraded Uniqure from a sell rating to a hold rating in a report on Friday, October 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $55.67.
Shares of Uniqure stock opened at $29.95 on Tuesday. The company has a current ratio of 7.56, a quick ratio of 7.56 and a debt-to-equity ratio of 0.05. Uniqure has a 52-week low of $16.50 and a 52-week high of $43.23.
Uniqure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.03. The business had revenue of $3.15 million during the quarter, compared to analyst estimates of $3.37 million. Uniqure had a negative return on equity of 58.49% and a negative net margin of 725.04%. As a group, sell-side analysts forecast that Uniqure will post -2.57 EPS for the current year.
In related news, Director Philip Astley-Sparke sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $30.39, for a total value of $151,950.00. Following the completion of the sale, the director now directly owns 23,252 shares in the company, valued at approximately $706,628.28. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.56% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of QURE. OppenheimerFunds Inc. acquired a new stake in Uniqure in the 2nd quarter worth approximately $63,553,000. Redmile Group LLC acquired a new stake in Uniqure in the 2nd quarter worth approximately $61,402,000. FMR LLC lifted its holdings in Uniqure by 16.6% in the 2nd quarter. FMR LLC now owns 3,694,681 shares of the biotechnology company’s stock worth $139,659,000 after purchasing an additional 526,283 shares during the last quarter. Federated Investors Inc. PA lifted its holdings in Uniqure by 18.9% in the 2nd quarter. Federated Investors Inc. PA now owns 1,091,280 shares of the biotechnology company’s stock worth $41,250,000 after purchasing an additional 173,281 shares during the last quarter. Finally, Baker BROS. Advisors LP lifted its holdings in Uniqure by 21.0% in the 2nd quarter. Baker BROS. Advisors LP now owns 605,000 shares of the biotechnology company’s stock worth $22,869,000 after purchasing an additional 105,000 shares during the last quarter. Hedge funds and other institutional investors own 60.62% of the company’s stock.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Recommended Story: 52-Week High/Low
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.